High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes

The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (IHC) that will identify patients likely to benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Ven, Rieneke, Niemeijer, Anna-Larissa N., Stam, Anita G.M., Hashemi, Sayed M.S., Slockers, Christian G., Daniels, Johannes M., Thunnissen, Erik, Smit, Egbert F., de Gruijl, Tanja D., de Langen, Adrianus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441512/
https://www.ncbi.nlm.nih.gov/pubmed/28560238
http://dx.doi.org/10.1183/23120541.00110-2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441512/
https://www.ncbi.nlm.nih.gov/pubmed/28560238
http://dx.doi.org/10.1183/23120541.00110-2016

Ejemplares similares